FLT3 and acute lymphoblastic leukemia: Therapeutic targeting of FLT3 and other non-kinase dependencies in KMT2A-R ALL, including DOT1L and menin, have demonstrated robust activity in preclinical studies and have been translated to the clinic [7–11].